CJC-1295 Guide

CJC-1295 is a synthetic analog of growth hormone-releasing hormone, usually shortened to GHRH. The best-known published human work studied a long-acting, albumin-binding form designed to stimulate the pituitary GH/IGF-1 axis for longer than native GHRH. [1][2]

The practical distinction matters: many online listings use CJC-1295 loosely, sometimes separating "with DAC" and "without DAC" products. This draft focuses on the CJC-1295 described in the primary human literature as a long-acting GHRH analog, not on consumer peptide-market naming. [1]

CJC-1295 should be discussed as an investigational research compound, not as an established wellness treatment. The human evidence base is small, older, and mainly biomarker-oriented: it shows changes in growth hormone and IGF-1, but it does not prove broad claims about muscle gain, fat loss, recovery, sleep, or anti-aging outcomes. [1][2][3]

Native GHRH is a hypothalamic signal that acts on pituitary somatotroph cells to promote growth hormone release. CJC-1295 was designed to mimic GHRH signaling while extending exposure through albumin binding. [1][2]

In the early human pharmacology study, CJC-1295 produced sustained GH and IGF-1 increases after controlled subcutaneous administration. The same paper estimated a multi-day half-life, which helps explain why the DAC-style compound behaves differently from short-acting GHRH analogs. [1]

Another human study found that GH pulsatility was preserved after CJC-1295 exposure, with higher trough and mean GH secretion and increased IGF-1. That is mechanistically interesting, but it remains a biomarker finding rather than proof of a specific clinical benefit. [2]

The central human study was a pair of randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults. It reported dose-dependent increases in mean plasma growth hormone and IGF-1, with effects lasting days to weeks depending on the measurement and study phase. [1]

The same paper reported no serious adverse reactions in the studied healthy volunteers and described CJC-1295 as relatively well tolerated in that limited setting. This should not be generalized into long-term safety, treatment efficacy, or safety for unregulated products. [1][3]

A separate small clinical trial in healthy men used frequent overnight blood sampling and found preserved pulsatile GH secretion after CJC-1295, while basal GH, mean GH, and IGF-1 increased. This supports pathway activity, not consumer outcome claims. [2]

There is preclinical work in GHRH-knockout mice showing growth and body-composition effects under controlled experimental conditions. Animal data can help explain biology, but it should not be presented as evidence that CJC-1295 improves human body composition or recovery. [6]

Claim: "Raises growth hormone and IGF-1." Evidence: supported as a pharmacodynamic biomarker effect in small, controlled human studies of the long-acting CJC-1295 compound. [1][2]

Claim: "Improves muscle gain, fat loss, recovery, sleep, or anti-aging." Evidence: not established by large, long-term, patient-centered CJC-1295 outcome trials. These claims are usually extrapolated from the GH/IGF-1 pathway, animal studies, or general growth-hormone biology rather than direct CJC-1295 clinical outcome evidence. [1][2][6]

Claim: "Can substitute for prescribed endocrine care." Evidence: not supported. Evaluation of suspected growth hormone deficiency or other endocrine disease belongs with qualified clinicians using validated diagnostic pathways and approved therapies where appropriate. [4][5]

The early healthy-adult trial reported no serious adverse reactions in that limited setting, but the sample size and follow-up were not enough to establish broad long-term safety. Biomarker activity over days is not the same as a complete safety profile. [1]

FDA materials specifically flag compounded drugs containing CJC-1295 as having potential safety risks, including immunogenicity for some routes of administration, peptide-related impurities, API characterization complexity, limited clinical data, and serious adverse events associated with CJC-1295 such as increased heart rate and systemic vasodilatory reaction. [3]

FDA also emphasizes that compounded drugs are not FDA-approved, meaning FDA does not verify their safety, effectiveness, or quality before marketing. For peptides sold outside regulated drug pathways, identity, purity, sterility, potency, and labeling are separate safety concerns. [4][5]

Athletes should treat CJC-1295 as a prohibited-substance risk. WADA lists growth hormone-releasing factors, including GHRH analogs such as CJC-1295, within the prohibited peptide hormone/growth factor category. [7]

Because this review did not identify an FDA-approved CJC-1295 prescribing label, there is no official consumer storage standard to cite. Storage language found on seller pages should not be treated as proof of product legitimacy, sterility, potency, or safety. [3][4][5]

For regulated medicines, handling instructions come from validated manufacturing, packaging, stability, and labeling controls. For compounded or research-market peptides, FDA highlights that quality problems can include contamination or incorrect active-ingredient strength. [4][5]

This page should not provide reconstitution steps, injection technique, storage shortcuts, or dosing schedules. Any legitimate handling requirements would need to come from a qualified study protocol, official label, or licensed clinical setting. [4][5]